Navigation Links
Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting
Date:11/12/2010

DANBURY, Conn., Nov. 12, 2010 /PRNewswire/ -- Scientists from Biodel Inc. (Nasdaq: BIOD) reported new findings from the company's Linjeta™, insulin glargine, "smart" basal insulin and stabilized glucagon development programs in poster presentations yesterday and today at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD.  

Dr. Frank Flacke presented results of a Phase 1 single-center, double-blind, randomized crossover trial in 13 subjects with type 1 diabetes who received a once-daily injection of Linjeta™ or one of two modified formulations of Linjeta™, each on a separate day ("Characterization of Pharmacokinetics and Toleration of Three Variant Formulations of Linjeta™").  The purpose of the study was to compare the pharmacokinetic characteristics and toleration of Linjeta™ to the two modified formulations.  The study found that the modified formulations were associated with improved toleration profiles and lower maximal insulin concentrations compared to Linjeta.   Modified formulation BIOD-102 was associated with a similar rate of absorption as Linjeta.

Dr. Roderike Pohl reported results of in vitro and preclinical testing of a modified form of insulin glargine in diabetic miniature swine to assess its duration of activity and pharmacokinetic profile compared to insulin glargine ("A New Formulation of Insulin Glargine with an Extended Release Profile").  The study found that certain excipients, when combined with insulin glargine, reduced the drug's solubility and could prolong its duration of action to greater than 24 hours compared to an average 18.5 hours for insulin glargine.

Nandini Kashyap described results of in vitro and in vivo studies in diabetic swine which showed that a "smart" basal insulin formulation can release insulin in response to changing glucose conce
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting
2. Biodel Awarded $1.2 Million in Therapeutic Discovery Research Grants From IRS
3. FDA Issues Complete Response Letter to Biodel Regarding New Drug Application for Linjeta™
4. Biodel to Present at Upcoming Conferences
5. Biodel Reports Research Progress in Poster Session on Short-Acting Insulins at 46th EASD Annual Meeting
6. Biodel Appoints Arthur Urciuoli to its Board of Directors
7. Biodel to Raise $9.4 Million Through Registered Direct Offering
8. Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
9. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
10. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
11. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technology used to develop and produce enzymes ... biopharmaceuticals, and industrial enzymes industries, today announced the ... Bioenergy for commercial scale production of Abengoa,s proprietary ... developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... and service provider for the medical industries, announced today the expansion ... New York City . genae Americas was incorporated ... is strategically centered in one of the highest concentrations of medical ... Philippe Kassab , President at genae Americas. "The expansion of genae ...
(Date:10/1/2014)... Oct. 1, 2014  Varian Medical Systems (NYSE: ... results for the fourth quarter of fiscal year 2014 ... 22, 2014.  The news release will be followed by ... p.m. PT.  The news release and a link to ... company website at: www.varian.com/investor .  To access the ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3genae Opens Offices in New York City 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
... Sept. 9 Luminex Corporation (Nasdaq: LMNX ... Global Life Sciences Conference to be held September 20 ... (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) (Logo: ... Patrick J. Balthrop, president and chief executive officer, will ...
... NEW YORK, Sept. 9 Reportlinker.com announces that a new ... US Enzymes Market http://www.reportlinker.com/p091893/US-Enzymes-Market.html ... 2014 Demand for enzymes in the US is forecast to ... 2014. Solid industry growth in recent years has been founded ...
Cached Medicine Technology:Luminex Corporation to Present at UBS Global Life Sciences Conference 2Reportlinker Adds US Enzymes Market 2Reportlinker Adds US Enzymes Market 3Reportlinker Adds US Enzymes Market 4Reportlinker Adds US Enzymes Market 5Reportlinker Adds US Enzymes Market 6Reportlinker Adds US Enzymes Market 7Reportlinker Adds US Enzymes Market 8
(Date:10/1/2014)... Farmington Company today announced it has ... visual identity helping brokers, consultants and companies to ... create greater benefit communication synergies. They unveiled a ... customers to better leverage Farmington Company’s industry-tested experience ... the rebrand is the refreshed tagline: For the ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... Between 23 million and 50 million ... to figures from the National Institutes of Health (NIH) ... many of them have something else in common: They ... disease. Gluten Free Therapeutics, makers of CeliVites ... disease by publishing a series of blog posts aimed ...
(Date:10/1/2014)... City, NJ (PRWEB) October 01, 2014 Diet ... with their intentions to lose weight and their dieting attempts ... unhealthy, fatty foods. Including hormone diet treatments into ... only allows patients to see fast and effective weight loss ... and begin forming healthy habits to maintain their weight for ...
(Date:10/1/2014)... October 01, 2014 Anti Aging Clinic ... skin rejuvenating destination of choice, is announcing a discounted ... through to December. , “We’re doing this because we ... to our top skin clinic in Toronto,” says Dr. ... so much at Anti Aging Clinic, including laser facials, ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... -- Deadly and difficult to treat, liver cancer has long ... and prevent recurrence. But Mayo Clinic Cancer Center, in collaboration ... of Hepatology that the protein sulfatase 2 (SULF2) may provide ... new therapies. , Mayo Clinic Cancer Center leads the field ...
... Methodist Healthcare -- Memphis,Hospitals ("Methodist") announced today that ... designated maturities of the,Bonds. The tender offer was extended ... April 9, 2008 at 5:00 pm, New York City ... be terminated is applicable to,the following: for the Series ...
... CITY, Calif., April 10 Abaxis, Inc.,(Nasdaq: ... analysis systems, announced today that Clint Severson, Chief,Executive ... 37th,Annual Institutional Unconference on Tuesday, April 15, 2008 ... Atlanta, Georgia., Interested investors are invited to ...
... ANN ARBOR, Mich.---Female penguins mate with males who bring ... gain access to the most productive flowers guarded by ... affluent college students who don,t need resources will still ... Kruger, research scientist at the University of Michigan School ...
... trials could start in several years, study says , , THURSDAY, ... the formation of scar tissue at the site of a ... has been developed by researchers at Northwestern University in Chicago. ... to regrow after a spinal injury, but they,re blocked by ...
... inhibitors exhibit cancer-killing activities in cultured cells. While ... in clinical trials, just how they execute their ... of recent papers, Vanderbilt-Ingram Cancer Center investigators provide ... damage cancer cells and offer clues about possible ...
Cached Medicine News:Health News:Mayo Clinic identifies treatment target for liver cancer recurrence and survival 2Health News:Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers 2Health News:Abaxis to Present at the SunTrust Robinson Humphrey's 37th Annual Institutional Unconference 2Health News:Just like penguins and other primates, people trade sex for resources 2Health News:Gel Enables Severed Spinal Cord Fibers to Regrow 2Health News:The good and bad side of anti-cancer compounds 2Health News:The good and bad side of anti-cancer compounds 3
... Strep A Test is a color immunochromatographic ... uses antibody labeled color particles coated at ... DLT allows greater sensitivity than the conventional ... the test procedure, a throat swab is ...
... The IntraLase FS laser introduces new high ... Surgeons now have the opportunity to offer ... to a microkeratome for creating the corneal ... FS laser and proprietary IntraLASIK software, surgeons ...
... Teco Diagnostics manufactures fine urine ... our urine chemistry reagent strips from ... to offer more economical prices compared ... the quality. Teco Diagnostics urine reagent ...
... term complications associated with diabetes continue to ... and quality of life of patients, in ... complications are known to be associated with ... that the level of haemoglobin A1c (HbA1c) ...
Medicine Products: